6/3/2022 - 6/7/2022

2022 ASCO® Annual Meeting

Tempus’ mission is to apply data and AI to diagnostics in order to route every patient to a personalized, optimal therapeutic path. We’re helping treat the patients of today while finding cures for the patients of tomorrow. We are pleased to share our latest scientific and clinical research findings during the 2022 ASCO® Annual Meeting (Booth #5063).

Tempus Reception

Join us for lab tours, interactive demos, conversation, food, and drinks on Sunday, June 5, 2022 @ 6 – 8 pm CDT

Tempus
600 West Chicago Avenue Chicago, IL 60654. Transportation from McCormick Place provided. Please contact events@tempus.com with any questions.

RSVP required

Tempus Industry Expert Theater

Precision Oncology Now: Enhancing patient care with integrated clinical applications that are powered by multimodal data

Live Session: 6/6/2022 @ 9:30 am – 10:30 am CDT

  • Learn to empower your practice and research program through Tempus’ comprehensive portfolio of NGS offerings. Discover how one of the world’s largest cancer platforms accelerates discovery, provides personalized treatment options, and precisely matches patients to clinical trials.
  • Join the Tempus team at booth #5063 directly following the session for a live Q&A with the presenters, Dr. James Chen and Dr. Calvin Chao

Oral Presentation and Poster Highlights

  • UPCOMING WEBINAR:

    Operational Metrics for the ELAINE II study Combining a Traditional Approach with a Just-in-Time Model (Abstract #1504)

    Presenter: Sibel Blau (Northwestern Medical)

    Live Session: 6/6/2022 @ 3:00 pm – 6:00 pm CDT

    By combining TIME trial and traditional enrollment models clinical trials may recruit more patients and reach full enrollment faster

    Read more
  • UPCOMING WEBINAR:

    Dual tissue and plasma testing improves detection of actionable variants in patients with solid cancers (Poster #9)

    Presenter: Wade Iams; Vanderbilt

    Live Session: 6/5/2022 @ 8:00 am – 11:00 am CDT & 4:30 pm – 6:00 pm CDT

    Performing liquid biopsy in addition to tissue based testing identifies more patients with clinically actionable variants

    Read more
  • UPCOMING WEBINAR:

    Clinical RNA-sequencing improves the detection of actionable fusions over DNA-sequencing alone (Poster #69)

    Lead Author: Jack Michuda; Tempus Labs

    Live Session: 6/6/2022 @ 3:00 pm to 6:00 pm CDT

    In the largest fusion analysis of its kind Tempus reviewed a real-world data set of 77,400 patient records for improvement in clinically actionable fusion detection due to the inclusion of RNA sequencing; The inclusion of RNA sequencing improves fusion detection vs DNA alone

    Read more
  • UPCOMING WEBINAR:

    Real world data enables large-scale assessment of WHO CNS5 glioma classification (Poster #356)

    Presenter: Robin Buerki; Northwestern

    Live Session: 6/5/2022 @ 8:00 am – 11:00 am CDT & 11:30 am – 1:00 pm CDT

    Researchers analyzed a de-identified dataset of CNS tumors and found that reclassifying according to the new WHO classification system resulted in more accurate prognostic stratification than the original diagnosis

    Read more
  • UPCOMING WEBINAR:

    Genetic ancestry differences in tumor mutation and expression in early and average onset colorectal cancer (Poster #413)

    First Author: Nina Sanford; UTSW

    6/4/2022 @ 8:00 am – 11:00 am CDT

    Used genetic ancestry instead of race/ethnicity classes to provide a more quantitative and precise profile of shared genetic background that can underlie biological race differences in cancer etiology and outcomes

    Read more
  • UPCOMING WEBINAR:

    Paired tumor/normal sequencing reduces apparent racial differences in tumor mutational burden (TMB) (Poster #130)

    First Author: Christopher W. Seder; Rush University

    6/5/2022 @ 8:00 am – 11:00 am CDT

    The use of xT tumor/normal match reduced apparent discrepancy in TMB levels between racial groups, particularly for Black and Asian patients

    Read more

Poster Presentations

  • UPCOMING WEBINAR:

    Comparative Analysis of the Targetable Landscape in KRAS-mutated and wild-type Pancreatic Adenocarcinoma (Poster #140)

    Todd Knepper; Moffitt, Prateek Gulhati; Rutgers

    6/4/2022 @ 8:00 am – 11:00 am CDT

    Read more
  • UPCOMING WEBINAR:

    Natural Language Processing-Optimized Case Selection for RWE Studies (Poster #149)

    Jacob Koskimaki; Astrazeneca

    6/4/2022 @ 1:15 pm – 4:15 pm CDT

    Read more
  • UPCOMING WEBINAR:

    Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E–mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immuno-metabolomic biomarkers (Poster #58)

    Mohamed E. Salem; Levine Cancer Institute

    6/5/2022 @ 8:00 am – 11:00 am CDT

    Read more
  • UPCOMING WEBINAR:

    Genomic landscape of SMARCA4-deficient lung tumors by clinical RNA sequencing (Poster #110)

    Brian Pham; UC Davis

    6/5/2022 @ 8:00 am – 11:00 am CDT

    Read more
  • UPCOMING WEBINAR:

    Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR) colorectal cancer (CRC) (Poster #59)

    Mohamed E. Salem; Levine Cancer Institute

    6/5/2022 @ 8:00 am – 11:00 am CDT

    Read more
  • UPCOMING WEBINAR:

    Prevalence of high tumor mutational burden (TMB-H) and microsatellite instability-high (MSI-H) status in neuroendocrine neoplasms. (Poster #280)

    Sukhmani Kaur Padda; Cedars Sinai

    6/5/2022 @ 8:00 am – 11:00 am CDT

    Read more

This is data-driven precision medicine

This is the future of healthcare.

CONTACT TEMPUS